Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932979 | 1.00 | MEN1 (0.58) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL20795542 | 1.00 | MEN1 (0.58) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL30741566 | 1.00 | MEN1 (0.58) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL932549 | 0.98 | MEN1 (0.57) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL932548 | 0.98 | MEN1 (0.57) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL24168763 | 0.95 | MEN1 (0.54) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL22040843 | 0.88 | MEN1 (0.71) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL20220408 | 0.84 | MEN1 (0.45) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL16309081 | 0.84 | MEN1 (0.45) | MEN1KMT2AKCNH2CCNT1CDK9 | |
| SCHEMBL31518263 | 0.83 | MEN1 (0.78) | MEN1KMT2AKCNH2TACR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4585598-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024051631-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州朗睿生物医药有限公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117659020-A | Imidazo [1,2-b ] pyridazine derivative, and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117659043-A | Macrocyclic imidazo [1,2-b ] pyridazine derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117624166-A | Triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117586277-A | Macrocyclic triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024032390-A1 | MACROCYCLIC TRIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州朗睿生物医药有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2725028-A1 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors | Array Biopharma, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8513263-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| EP-2350071-A1 | SUBSTITUTED PYRAZOLOÝ1,5-a¨PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885KCNH2 2376/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | MEN1 2927/4885KMT2A 2437/4885KCNH2 2530/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | MEN1 4351/4885KMT2A 3339/4885KCNH2 2293/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | MEN1 3952/4885KMT2A 3118/4885KCNH2 1604/4885 |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, ROR1 | MEN1 1969/4885KMT2A 3437/4885KCNH2 1117/4885 |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | P2RX7, P2RX1, P2RX3 | MEN1 3917/4885KMT2A 3101/4885KCNH2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.